These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 24789797

  • 1. Production and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24.
    Gupta PK, Mukherjee P, Dhawan S, Pandey AK, Mazumdar S, Gaur D, Jain SK, Chauhan VS.
    Clin Vaccine Immunol; 2014 Jun; 21(6):886-97. PubMed ID: 24789797
    [Abstract] [Full Text] [Related]

  • 2. Plasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response.
    Mazumdar S, Mukherjee P, Yazdani SS, Jain SK, Mohmmed A, Chauhan VS.
    Infect Immun; 2010 Feb; 78(2):872-83. PubMed ID: 19933832
    [Abstract] [Full Text] [Related]

  • 3. Antigenicity of a Bacterially Expressed Triple Chimeric Antigen of Plasmodium falciparum AARP, MSP-311 and MSP-119: PfAMSP-Fu35.
    Kalra A, Edula JR, Gupta PK, Pandey AK, Chauhan VS.
    PLoS One; 2016 Feb; 11(10):e0165720. PubMed ID: 27798691
    [Abstract] [Full Text] [Related]

  • 4. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM, Miura K, Sullivan J, Long CA, Barnwell JW.
    Malar J; 2016 Mar 15; 15():159. PubMed ID: 26975721
    [Abstract] [Full Text] [Related]

  • 5. Poly(I:C) adjuvant strongly enhances parasite-inhibitory antibodies and Th1 response against Plasmodium falciparum merozoite surface protein-1 (42-kDa fragment) in BALB/c mice.
    Mehrizi AA, Rezvani N, Zakeri S, Gholami A, Babaeekhou L.
    Med Microbiol Immunol; 2018 Apr 15; 207(2):151-166. PubMed ID: 29397427
    [Abstract] [Full Text] [Related]

  • 6. Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants.
    Sachdeva S, Mohmmed A, Dasaradhi PV, Crabb BS, Katyal A, Malhotra P, Chauhan VS.
    Vaccine; 2006 Mar 15; 24(12):2007-16. PubMed ID: 16377036
    [Abstract] [Full Text] [Related]

  • 7. Inclusion of an Optimized Plasmodium falciparum Merozoite Surface Protein 2-Based Antigen in a Trivalent, Multistage Malaria Vaccine.
    Eacret JS, Parzych EM, Gonzales DM, Burns JM.
    J Immunol; 2021 Apr 15; 206(8):1817-1831. PubMed ID: 33789984
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Generation, characterization and immunogenicity of a novel chimeric recombinant protein based on Plasmodium vivax AMA-1 and MSP119.
    Rocha MV, Françoso KS, Lima LC, Camargo TM, Machado RLD, Costa FTM, Rénia L, Nosten F, Russell B, Rodrigues MM, Soares IS.
    Vaccine; 2017 Apr 25; 35(18):2463-2472. PubMed ID: 28341111
    [Abstract] [Full Text] [Related]

  • 10. Immune responses elicited by co-immunization of Plasmodium vivax and P. falciparum MSP-1 using prime-boost immunization strategies.
    Mehrizi AA, Zakeri S, Rafati S, Salmanian AH, Djadid ND.
    Parasite Immunol; 2011 Nov 25; 33(11):594-608. PubMed ID: 21883290
    [Abstract] [Full Text] [Related]

  • 11. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.
    Bargieri DY, Leite JA, Lopes SC, Sbrogio-Almeida ME, Braga CJ, Ferreira LC, Soares IS, Costa FT, Rodrigues MM.
    Vaccine; 2010 Apr 01; 28(16):2818-26. PubMed ID: 20170765
    [Abstract] [Full Text] [Related]

  • 12. Enhanced protection against malaria by a chimeric merozoite surface protein vaccine.
    Shi Q, Lynch MM, Romero M, Burns JM.
    Infect Immun; 2007 Mar 01; 75(3):1349-58. PubMed ID: 17158895
    [Abstract] [Full Text] [Related]

  • 13. Polymorphism and epitope sharing between the alleles of merozoite surface protein-1 of Plasmodium falciparum among Indian isolates.
    Mamillapalli A, Sunil S, Diwan SS, Sharma SK, Tyagi PK, Adak T, Joshi H, Malhotra P.
    Malar J; 2007 Jul 20; 6():95. PubMed ID: 17659072
    [Abstract] [Full Text] [Related]

  • 14. Maintaining immunogenicity of blood stage and sexual stage subunit malaria vaccines when formulated in combination.
    Parzych EM, Miura K, Long CA, Burns JM.
    PLoS One; 2020 Jul 20; 15(4):e0232355. PubMed ID: 32348377
    [Abstract] [Full Text] [Related]

  • 15. Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-1(42) malaria vaccine.
    Angov E, Aufiero BM, Turgeon AM, Van Handenhove M, Ockenhouse CF, Kester KE, Walsh DS, McBride JS, Dubois MC, Cohen J, Haynes JD, Eckels KH, Heppner DG, Ballou WR, Diggs CL, Lyon JA.
    Mol Biochem Parasitol; 2003 May 20; 128(2):195-204. PubMed ID: 12742586
    [Abstract] [Full Text] [Related]

  • 16. Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant.
    Xue X, Ding F, Zhang Q, Pan X, Qu L, Pan W.
    Vaccine; 2010 Apr 19; 28(18):3152-8. PubMed ID: 20197139
    [Abstract] [Full Text] [Related]

  • 17. Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.
    Chitnis CE, Mukherjee P, Mehta S, Yazdani SS, Dhawan S, Shakri AR, Bhardwaj R, Gupta PK, Hans D, Mazumdar S, Singh B, Kumar S, Pandey G, Parulekar V, Imbault N, Shivyogi P, Godbole G, Mohan K, Leroy O, Singh K, Chauhan VS.
    PLoS One; 2015 Apr 19; 10(4):e0117820. PubMed ID: 25927360
    [Abstract] [Full Text] [Related]

  • 18. Expression of an immunologically reactive merozoite surface protein (MSP-1(42)) in E. coli.
    Leung WH, Meng ZQ, Hui G, Ho WK.
    Biochim Biophys Acta; 2004 Nov 18; 1675(1-3):62-70. PubMed ID: 15535968
    [Abstract] [Full Text] [Related]

  • 19. Non-variant specific antibody responses to the C-terminal region of merozoite surface protein-1 of Plasmodium falciparum (PfMSP-1(19)) in Iranians exposed to unstable malaria transmission.
    Zakeri S, Mehrizi AA, Zoghi S, Djadid ND.
    Malar J; 2010 Sep 16; 9():257. PubMed ID: 20846388
    [Abstract] [Full Text] [Related]

  • 20. Malaria vaccine-related benefits of a single protein comprising Plasmodium falciparum apical membrane antigen 1 domains I and II fused to a modified form of the 19-kilodalton C-terminal fragment of merozoite surface protein 1.
    Faber BW, Remarque EJ, Morgan WD, Kocken CH, Holder AA, Thomas AW.
    Infect Immun; 2007 Dec 16; 75(12):5947-55. PubMed ID: 17938224
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.